Dr. Kenya R. Thomas, MD
General Practice (General Practice Physician)
1133 E 83rd St Unit 108
Chicago, IL 60619
Who else practices at this address →
Cook County includes primary care (3% of residents) and mental health (4% of residents) shortage areas. About shortage areas
At a glance
- In the NPI registry since
- 2014
Licensed in Illinois since 2017, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2014Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
General Practice Physician primary
IL license 036144728 (first issued 2017; active) - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 12 companies reported 108 payments worth $2,220 in total to this clinician.
| Viiv Healthcare Company | $1,167 |
|---|---|
| Merck Sharp & Dohme LLC | $286 |
| Gilead Sciences, Inc. | $261 |
| Theratechnologies Inc. | $134 |
| EMD Serono, Inc. | $82.91 |
| Alkermes, Inc. | $75.31 |
| Napo Pharmaceuticals Inc | $66.87 |
| Novo Nordisk Inc | $48.07 |
| Food and Beverage | $2,220 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $196,135 in research payments for these studies, mostly to the institutions running them.
- Roche Cancer Screening Collection Study
Genentech, Inc. - Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)
Sanofi US Services Inc. · Completed · NCT04701983
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.